Big Pharma's TPP Protections For Biologics Face New Attacks

Law360, New York (July 17, 2015, 4:37 PM EDT) -- A group of lawmakers, generic-drug industry advocates and public health experts on Friday denounced proposals in the Trans-Pacific Partnership to strengthen exclusivity protections for brand-name biologics, warning that the provisions would seriously harm access to affordable copycat medicines.

The objections were voiced in a media briefing with Democratic Reps. Jan Schakowsky of Illinois and Rosa DeLauro of Connecticut as well as representatives of Mylan Inc., AARP, Doctors Without Borders and the American Foundation for AIDS Research. The briefing represented a marked contrast with advocacy from Republicans who’ve steadfastly supported robust TPP protections for biologics, which have shown great potential to fulfill...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS